A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced Non-Small Cell Lung Cancer With an FGFR Alteration Who Progressed on Previous Therapy (FIGHT 210)
Latest Information Update: 08 Aug 2024
At a glance
- Drugs Pemigatinib (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms FIGHT 210
- Sponsors Incyte Corporation
Most Recent Events
- 20 Nov 2023 Status changed from active, no longer recruiting to completed.
- 01 Jun 2023 Planned End Date changed from 19 Jan 2026 to 31 Dec 2023.
- 01 Jun 2023 Planned primary completion date changed from 19 Jan 2026 to 12 Oct 2023.